Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
Business

EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70%

EyePoint said its experimental drug to ​treat a serious eye disease that affects older people failed in a late-stage trial, sending its shares plunging over 65% in premarket ‌trading ⁠on Monday.

The ⁠company was testing the drug, Duravyu, against approved treatment Eylea ​in patients with wet age-related macular degeneration, a leading cause of vision ​loss.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.